[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"current-user-roles":3,"user-subscription":3,"bill:119-hr-1405":4},null,{"bill":5,"indexable":225,"summaries":226,"cosponsors":232,"cosponsorSlugs":237,"actions":239,"amendments":257,"amendmentSponsorSlugs":258,"linkages":259,"sponsorSlug":260},{"statusDate":6,"sponsor":7,"updateDate":15,"cboCostEstimates":16,"originChamber":17,"congress":18,"isByRequest":19,"title":20,"createdAt":21,"committeeReports":22,"cosponsorCount":23,"onBehalfOfSponsor":3,"adminOverride":3,"amendmentCount":24,"actionCount":25,"popularTitle":3,"laws":3,"billType":26,"introducedDate":6,"committees":27,"congressGovUrl":28,"constitutionalAuthority":29,"policyArea":30,"deletedAt":3,"latestAction":31,"billNumber":33,"cosponsorCountIncludingWithdrawn":23,"status":34,"shortTitle":20,"officialTitle":35,"keyMilestoneCount":36,"subjects":37,"updatedAt":44,"policyAreaLower":45,"searchTokens":46,"committeeCodes":224},"2025-02-18",{"firstName":8,"lastName":9,"district":10,"fullName":11,"state":12,"party":13,"bioguideId":14},"Vern","Buchanan","16","Rep. Buchanan, Vern [R-FL-16]","FL","R","B001260","2025-07-30T21:27:37Z",[],"House",119,false,"Enhancing Domestic Drug Manufacturing Competitiveness Act","2026-05-11T16:09:34.693Z",[],1,0,3,"hr",[],"https:\u002F\u002Fwww.congress.gov\u002Fbill\u002F119th-congress\u002Fhouse-bill\u002F1405","\u003Cpre>\n[Congressional Record Volume 171, Number 32 (Tuesday, February 18, 2025)]\n[House]\nFrom the Congressional Record Online through the Government Publishing Office [\u003Ca href=\"https:\u002F\u002Fwww.gpo.gov\">www.gpo.gov\u003C\u002Fa>]\nBy Mr. BUCHANAN:\nH.R. 1405.\nCongress has the power to enact this legislation pursuant\nto the following:\nArticle 1, section 8\n[Page H723]\n\u003C\u002Fpre>","Health",{"date":6,"text":32},"Referred to the House Committee on Energy and Commerce.",1405,"in_committee","To direct the Comptroller General of the United States to conduct a study to assess the key regulatory barriers that impede the expansion or siting of new pharmaceutical manufacturing facilities in the United States, and for other purposes.",2,[38,39,40,41,42,43],"Administrative law and regulatory procedures","Congressional oversight","Environmental regulatory procedures","Government studies and investigations","Manufacturing","Prescription drugs","2026-05-23T05:52:53.325Z","health",[47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114,115,116,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136,137,138,139,140,141,142,143,144,145,146,147,148,149,150,151,152,153,154,155,156,157,158,159,160,161,162,163,164,165,166,167,168,169,170,171,172,173,174,175,176,177,178,179,180,181,182,183,184,185,186,187,188,189,190,191,192,193,194,195,196,197,198,199,200,201,202,203,204,205,206,207,208,209,210,211,212,213,214,215,216,217,218,219,220,221,222,223,10],"enhancing","en","enh","enha","enhan","enhanc","enhanci","enhancin","domestic","do","dom","dome","domes","domest","domesti","drug","dr","dru","manufacturing","ma","man","manu","manuf","manufa","manufac","manufact","manufactu","manufactur","manufacturi","manufacturin","competitiveness","co","com","comp","compe","compet","competi","competit","competiti","competitiv","competitive","competitiven","competitivene","competitivenes","act","to","direct","di","dir","dire","direc","the","comptroller","compt","comptr","comptro","comptrol","comptroll","comptrolle","general","ge","gen","gene","gener","genera","of","united","un","uni","unit","unite","states","st","sta","stat","state","conduct","con","cond","condu","conduc","study","stu","stud","assess","as","ass","asse","asses","key","regulatory","re","reg","regu","regul","regula","regulat","regulato","regulator","barriers","ba","bar","barr","barri","barrie","barrier","that","th","tha","impede","im","imp","impe","imped","expansion","ex","exp","expa","expan","expans","expansi","expansio","or","siting","si","sit","siti","sitin","new","pharmaceutical","ph","pha","phar","pharm","pharma","pharmac","pharmace","pharmaceu","pharmaceut","pharmaceuti","pharmaceutic","pharmaceutica","facilities","fa","fac","faci","facil","facili","facilit","faciliti","facilitie","in","and","for","other","ot","oth","othe","purposes","pu","pur","purp","purpo","purpos","purpose","rep","buchanan","bu","buc","buch","bucha","buchan","buchana","vern","ve","ver","fl",[],true,[227],{"versionCode":228,"actionDate":6,"actionDesc":229,"text":230,"updateDate":231},"00","Introduced in House","\u003Cp>\u003Cstrong>Enhancing Domestic Drug Manufacturing Competitiveness Act\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>This bill requires the Government Accountability Office (GAO) to study and report to Congress on key regulatory barriers to pharmaceutical manufacturing in the United States. \u003C\u002Fp>\u003Cp>Specifically, GAO must identify and assess, including by engaging stakeholders, barriers that impede expansion or siting of pharmaceutical manufacturing facilities in the United States or make the United States less competitive than other countries as a location for such facilities. GAO must consider (1) whether environmental or other regulations significantly delay and increase the cost of expanding or siting pharmaceutical manufacturing facilities in the United States; (2) the potential impact of environmental and other regulations on pharmaceutical supply chain resiliency; and (3) specific actions for regulators to address the identified barriers. \u003C\u002Fp>\u003Cp>Finally, the report must include recommendations for streamlining regulatory barriers and facilitating technological solutions to foster U.S. pharmaceutical manufacturing. \u003C\u002Fp>","2025-07-30T21:26:28Z",[233],{"bioguideId":234,"fullName":235,"party":13,"state":12,"district":236,"sponsorshipDate":6,"isOriginalCosponsor":225,"withdrawn":19,"sponsorshipWithdrawnDate":3},"D000032","Rep. Donalds, Byron [R-FL-19]","19",{"D000032":238},"byron-donalds",[240,249,254],{"actionDate":6,"actionDateTime":3,"text":32,"type":241,"actionCode":242,"sourceSystem":243,"committees":245,"recordedVotes":3,"calendarNumber":3,"sequenceIndex":24,"isKeyMilestone":19},"IntroReferral","H11100",{"code":36,"name":244},"House floor actions",[246],{"name":247,"systemCode":248},"Energy and Commerce Committee","hsif00",{"actionDate":6,"actionDateTime":3,"text":229,"type":241,"actionCode":250,"sourceSystem":251,"committees":3,"recordedVotes":3,"calendarNumber":3,"sequenceIndex":36,"isKeyMilestone":225},"1000",{"code":252,"name":253},9,"Library of Congress",{"actionDate":6,"actionDateTime":3,"text":229,"type":241,"actionCode":255,"sourceSystem":256,"committees":3,"recordedVotes":3,"calendarNumber":3,"sequenceIndex":23,"isKeyMilestone":225},"Intro-H",{"code":252,"name":253},[],{},[],"vern-buchanan"]